Bayforest Capital Ltd Sells 4,061 Shares of Jazz Pharmaceuticals PLC $JAZZ

Bayforest Capital Ltd trimmed its position in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 70.1% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,730 shares of the specialty pharmaceutical company’s stock after selling 4,061 shares during the quarter. Bayforest Capital Ltd’s holdings in Jazz Pharmaceuticals were worth $228,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Philip James Wealth Mangement LLC lifted its stake in shares of Jazz Pharmaceuticals by 42.0% in the 2nd quarter. Philip James Wealth Mangement LLC now owns 15,797 shares of the specialty pharmaceutical company’s stock valued at $1,676,000 after purchasing an additional 4,675 shares during the last quarter. State of Alaska Department of Revenue raised its holdings in Jazz Pharmaceuticals by 75.1% during the 2nd quarter. State of Alaska Department of Revenue now owns 57,933 shares of the specialty pharmaceutical company’s stock valued at $6,147,000 after buying an additional 24,850 shares during the period. Kennedy Capital Management LLC bought a new stake in Jazz Pharmaceuticals in the second quarter worth $1,100,000. Wedge Capital Management L L P NC purchased a new position in Jazz Pharmaceuticals during the third quarter worth $27,834,000. Finally, Voya Investment Management LLC increased its position in Jazz Pharmaceuticals by 67.1% during the first quarter. Voya Investment Management LLC now owns 56,349 shares of the specialty pharmaceutical company’s stock valued at $6,996,000 after acquiring an additional 22,628 shares during the last quarter. 89.14% of the stock is currently owned by hedge funds and other institutional investors.

Jazz Pharmaceuticals Trading Down 0.8%

JAZZ opened at $162.43 on Wednesday. The company has a quick ratio of 1.44, a current ratio of 1.65 and a debt-to-equity ratio of 1.09. The stock’s fifty day moving average is $164.83 and its two-hundred day moving average is $138.64. The company has a market capitalization of $9.87 billion, a P/E ratio of -26.76, a PEG ratio of 0.75 and a beta of 0.27. Jazz Pharmaceuticals PLC has a 52 week low of $95.49 and a 52 week high of $182.99.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the stock. Piper Sandler restated an “overweight” rating and issued a $219.00 target price (up previously from $147.00) on shares of Jazz Pharmaceuticals in a report on Wednesday, December 10th. Needham & Company LLC boosted their target price on Jazz Pharmaceuticals from $210.00 to $235.00 and gave the company a “buy” rating in a research report on Monday. Bank of America increased their price target on Jazz Pharmaceuticals from $230.00 to $247.00 and gave the stock a “buy” rating in a report on Tuesday, November 18th. Morgan Stanley reaffirmed an “overweight” rating and issued a $225.00 price objective on shares of Jazz Pharmaceuticals in a research report on Thursday, January 8th. Finally, Robert W. Baird lifted their target price on Jazz Pharmaceuticals from $160.00 to $209.00 and gave the stock an “outperform” rating in a research report on Tuesday, November 18th. Thirteen research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Jazz Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $205.67.

Insider Activity

In other news, EVP Robert Iannone sold 7,159 shares of the business’s stock in a transaction dated Monday, November 17th. The shares were sold at an average price of $168.26, for a total value of $1,204,573.34. Following the completion of the sale, the executive vice president owned 72,628 shares in the company, valued at approximately $12,220,387.28. The trade was a 8.97% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Heather Ann Mcsharry sold 3,415 shares of the stock in a transaction that occurred on Thursday, November 20th. The shares were sold at an average price of $177.78, for a total transaction of $607,118.70. Following the transaction, the director owned 20,449 shares in the company, valued at approximately $3,635,423.22. This represents a 14.31% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 123,791 shares of company stock valued at $21,991,850. Company insiders own 4.30% of the company’s stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.